^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VG201

    i
    Other names: VG201, VG2025, ENTIcE, Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
    Associations

    News

    Trials
    Company:
    ViroGin Biotech
    Drug class:
    IL-15R stimulant, IL-12 stimulant, IL-15 stimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    Study of VG2025 Delivered Intraperitoneally in Patients with Advanced Solid Tumors with Carcinomatosis (clinicaltrials.gov)
    P1, N=0, Withdrawn, M.D. Anderson Cancer Center | N=21 --> 0 | Trial completion date: Mar 2030 --> Oct 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2028 --> Oct 2024
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Metastases
    |
    VG201
    1year
    The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors (ESMO Asia 2023)
    Nanostring analysis of paired biopsies from the PR pts demonstrated upregulation of integrin signaling pathway, antigen-presenting MHC (HLA-DQA1 and HLA-DRB1) and chemokine receptor (CMKLR1) genes, and activation of CD8+ T cells. Conclusions Monotherapy with VG2025 demonstrated activity with a well-tolerant safety profile in pts with advanced solid tumors that progressed after standard of care therapy.
    Clinical • P1 data • Oncolytic virus • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CEACAM5 (CEA Cell Adhesion Molecule 5) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • IL15 (Interleukin 15)
    |
    VG201
    over1year
    The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors. (ASCO 2023)
    Monotherapy activity was observed with an acceptable safety profile in heavily pretreated pts with advanced solid tumors. Clinical trial information: NCT05266612.
    Clinical • P1 data • Oncolytic virus • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CEACAM5 (CEA Cell Adhesion Molecule 5) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • IL15 (Interleukin 15)
    |
    VG201